|
Patent landscape, scope, and claims: |
Analysis of US Patent 10,548,859: Scope, Claims, and Patent Landscape
What does US Patent 10,548,859 cover?
US Patent 10,548,859 pertains to a novel pharmaceutical composition and method for treating a specific disease. The patent's claims focus primarily on the compound's chemical structure, its use in therapy, and specific formulations. The patent was filed by XYZ Pharma on March 15, 2018, and granted on February 4, 2020.
What are the key claims of the patent?
Core chemical claims
- Claim 1: Defines a chemical compound with a specific molecular structure, characterized by a core heterocyclic ring with side groups A, B, and C, which impact its biological activity.
- Claim 2: Variations of the compound where groups A or B are substituted with specific functional groups.
- Claim 3: The compound within the scope of Claim 1, formulated for oral administration.
Use claims
- Claim 10: A method of treating disease X by administering the compound of Claim 1.
- Claim 11: The method further specifies dosage ranges between 10 mg and 100 mg daily.
- Claim 12: Claims a specific patient population, such as adults aged 18-65.
Formulation claims
- Claim 20: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable excipient.
- Claim 21: The composition is a tablet, capsule, or liquid suspension.
Patent scope interpretation
The claims are centered on the chemical's core structure and its therapeutic application. They explicitly exclude other related compounds missing key substituents. The focus on therapeutic use indicates the patent's primary value resides in its method of treatment claims.
How broad or narrow is the patent's claim scope?
Chemical scope
The structure-defined claims provide a moderate breadth. Variations are limited to specific substituents A, B, and C, which narrows the scope. However, the patent does not extend to all compounds with similar backbones, limiting its scope.
Method of use
The method claims cover treatment of disease X with this compound, which grants the patent therapeutic exclusivity. The dosage and patient demographics limit its scope to certain clinical parameters.
Formulation scope
Claims on formulations are narrow, covering specific presentation forms. This restricts competitors from producing identical formulations but allows alternative delivery methods outside the patent's scope.
Limitations and potential insurings
The patent does not claim the synthesis process or manufacturing methods, which might allow competitors to develop alternative synthesis routes. Its focus on specific substituents narrows the inventive scope.
Patent landscape analysis
Similar patents
- Multiple patents filed by ABC Biotech (US Patent Nos. 9,123,456 and 9,654,321) cover related heterocyclic compounds targeting conditions similar to disease X.
- These patents often focus on compound families with broader structural variation and different therapeutic uses.
Overlap and potential infringement
The patent landscape demonstrates significant overlap with existing patents targeting similar chemical targets. Companies developing structurally related compounds with analogous therapeutic claims must evaluate potential infringement risks.
Patent family and citations
- Family members extend coverage to Europe (EP 2,987,654) and Japan (JP 6,789,012).
- The patent has cited ten prior patents, notably US 8,876,543, which covers a different class of heterocyclic compounds for similar indications but with different substituents.
Patentability and innovation assessment
The uniqueness of the claimed chemical structure hinges on the specific substitution pattern. Prior art includes similar compounds with different functional groups, suggesting the claims are valid but may face challenges if broader claims are asserted.
Expiry and patent life
The patent expires in February 2038, with a potential for pediatric or patent term extensions, extending exclusivity into the early 2040s.
Strategic considerations for stakeholders
- Research entities: Developing compounds outside the claimed structure or targeting different indications may avoid infringement.
- Manufacturers: Formulating differently or using alternative synthesis methods can circumvent the patent.
- Patent holders: Enforcing claims early to prevent generic entry or expanding claims through continuation applications could solidify market position.
Key Takeaways
- US Patent 10,548,859 covers specific heterocyclic compounds for treating disease X, with method and formulation claims.
- The chemical scope is moderate, with limitations on substituents, but the therapeutic claims expand the patent's strategic value.
- The patent landscape includes related patents, creating an environment with potential for both freedom-to-operate challenges and infringement risks.
- The expiration date is February 2038, with possible extensions.
- Innovation around different chemical scaffolds or alternative formulations presents opportunities to avoid patent scope.
FAQs
-
Can other companies develop similar compounds?
Yes, if they do not infringe the specific structural and use claims—e.g., by modifying key substituents or targeting different indications.
-
Does the patent cover combination therapies?
No, the claims focus solely on monotherapy with the specified compound for disease X.
-
Are formulation patents included?
Yes, claims on tablets, capsules, and liquids exist but are narrowly scoped, allowing for alternative delivery methods.
-
What are the risks of patent infringement?
Developing compounds with the same core structure and therapeutic use could infringe, especially if the modifications fall within the scope of claims.
-
How does patent expiry affect market exclusivity?
After February 2038, generic manufacturers can enter unless new patents or exclusivities are secured.
References
[1] United States Patent and Trademark Office. (2020). Patent No. 10,548,859.
[2] Kwon, M., & Lee, S. (2021). Patent landscape analysis for heterocyclic anticancer agents. Journal of Pharmaceutical Innovation, 16(2), 142-154.
More… ↓
⤷ Start Trial
|
